Twinbeech Capital LP Cure Vac N.V. Transaction History

Twinbeech Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $127,581 - $188,598	22,188 Added 47.86%	68,548 $413,000
Q3 2022 Nov 14, 2022	BUY	$7.48 - $15.24 $346,772 - $706,526	46,360 New	46,360 $365,000
Q2 2022 Aug 15, 2022	SELL	$13.18 - $19.41 $1.09 Million - $1.6 Million	-82,547 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $221,583 - $530,265	15,043 Added 22.28%	82,547 $1.62 Million
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $2.28 Million - $3.26 Million	67,504 New	67,504 $2.32 Million
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $465,211 - $703,578	-9,444 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$56.91 - $127.53 $537,458 - $1.2 Million	9,444 New	9,444 $694,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.